Related Experiment Video
Updated: Sep 20, 2025

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based
Titia G Meijer1,2,3, Luan Nguyen4,5, Arne Van Hoeck4,5
1Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. t.meijer@erasmusmc.nl.
Abstract:
Germline BRCA1/2 mutation status is predictive for response to Poly-[ADP-Ribose]-Polymerase (PARP) inhibitors in breast cancer (BC) patients. However, non-germline BRCA1/2 mutated and homologous recombination repair deficient (HRD) tumors are likely also PARP-inhibitor sensitive. Clinical validity and utility of various HRD biomarkers are under investigation. The REpair CAPacity (RECAP) test is a functional method to select HRD tumors based on their inability to form RAD51 foci. We investigated whether this functional test defines a similar group of HRD tumors as DNA-based tests. An HRD enriched cohort (n = 71; 52 primary and 19 metastatic BCs) selected based on the RECAP test (26 RECAP-HRD; 37%), was subjected to DNA-based HRD tests (i.e., Classifier of HOmologous Recombination Deficiency (CHORD) and BRCA1/2-like classifier). Whole genome sequencing (WGS) was carried out for 38 primary and 19 metastatic BCs. The RECAP test identified all bi-allelic BRCA deficient samples (n = 15) in this cohort. RECAP status partially correlated with DNA-based HRD test outcomes (70% concordance for both RECAP-CHORD and RECAP-BRCA1/2-like classifier). RECAP selected additional samples unable to form RAD51 foci, suggesting that this functional assay identified deficiencies in other DNA repair genes, which could also result in PARP-inhibitor sensitivity. Direct comparison of these HRD tests in clinical trials will be required to evaluate the optimal predictive test for clinical decision making.
Insights
The functional REpair CAPacity (RECAP) test identifies homologous recombination deficiency (HRD) tumors, including those not defined by DNA-based tests, suggesting broader utility for predicting Poly-[ADP-Ribose]-Polymerase inhibitor sensitivity in breast cancer patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Germline BRCA1/2 mutations predict Poly-[ADP-Ribose]-Polymerase (PARP) inhibitor response in breast cancer (BC).
- Homologous recombination repair deficient (HRD) tumors, even without germline BRCA1/2 mutations, may also respond to PARP inhibitors.
- Various HRD biomarkers are being investigated for clinical validity and utility.
Purpose of the Study:
- To evaluate if the functional REpair CAPacity (RECAP) test identifies a similar group of HRD tumors as DNA-based HRD tests.
- To assess the concordance between the RECAP test and established DNA-based HRD classifiers.
Main Methods:
- An HRD-enriched cohort of 71 breast cancer patients was selected using the RECAP test.
- Patients underwent DNA-based HRD testing, including the Classifier of HOmologous Recombination Deficiency (CHORD) and BRCA1/2-like classifier.
- Whole genome sequencing (WGS) was performed on a subset of samples.
Main Results:
- The RECAP test identified all 15 bi-allelic BRCA deficient samples in the cohort.
- RECAP status showed partial correlation with DNA-based HRD tests, with 70% concordance for both RECAP-CHORD and RECAP-BRCA1/2-like classifiers.
- The RECAP test identified additional HRD samples not detected by DNA-based tests, suggesting it captures deficiencies in other DNA repair genes.
Conclusions:
- The functional RECAP test identifies a significant proportion of HRD tumors, including those missed by DNA-based assays.
- RECAP may identify additional patients who could benefit from PARP inhibitor therapy.
- Further clinical trials are needed to compare HRD tests for optimal predictive value in clinical decision-making.
Related Concept Videos
Homologous Recombination
Long-patch Base Excision Repair
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Restarting Stalled Replication Forks
Base Excision Repair
The first step of...

